Cargando…
Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome
INTRODUCTION: Rituximab (RTX) effectively prevents relapses in patients with complicated steroid-sensitive nephrotic syndrome (SSNS). The 1-year relapse-free survival rate is approximately 30% in children after the first episode of SSNS treated with standardised corticosteroids. Whether the benefits...
Autores principales: | Liu, Jialu, Shen, Qian, Xie, Li, Wang, Jiyang, Li, Yaxuan, Chen, Jing, Fang, Xiaoyan, Tang, Xiaoshan, Qian, Biyun, Xu, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562314/ https://www.ncbi.nlm.nih.gov/pubmed/36223961 http://dx.doi.org/10.1136/bmjopen-2022-064216 |
Ejemplares similares
-
Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial
por: Hogan, Julien, et al.
Publicado: (2020) -
Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol
por: Ravani, Pietro, et al.
Publicado: (2017) -
Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol
por: Lugani, Francesca, et al.
Publicado: (2021) -
Rituximab Treatment for Nephrotic Syndrome in Children
por: Iijima, Kazumoto, et al.
Publicado: (2014) -
Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study
por: Dunn, Sarah, et al.
Publicado: (2022)